TABLE OF CONTENTS

1. Introduction 16

1.1 Scope of the Study. 16

2. Pharmaceutical Market - Key Takeaways 17

3. Research Methodology 21

3.1 Coverage. 22

3.2 Secondary Research. 23

3.3 Primary Research. 24

4. Pharmaceutical Market - Market Landscape 25

4.1 Overview. 25

4.2 PESTLE Analysis. 25

4.2.1 Political Factors. 25

4.2.2 Economic Factors. 25

4.2.3 Social Factors. 26

4.2.4 Technological Factors. 26

4.2.5 Legal Factors. 27

4.2.6 Environmental Factors. 27

4.3 Expert's Opinion. 28

4.4 Macro-Economic Framework of the U.S. 28

4.5 Import and Export Activities in the U.S. and Italy. 31

4.5.1 Import - Export Analysis. 31

4.5.2 US. 37

4.5.3 Italy. 50

4.6 Magazines, Publications, Universities, and Online Portals. 60

4.7 Events List 65

4.8 Trade Shows List 67

4.9 Useful Contacts -Events and Trade Shows, Associations, and Magazines. 68

4.9.1 Associations - MAIN PHARMACEUTICAL, VACCINE AND CONSUMER PRODUCT TRADE ASSOCIATIONS. 74

4.9.2 Magazines - Trade Magazines, Blogs, Journals, and Publications. 81

4.10 Information Regarding CDMOs. 84

4.10.1 Surplus/Deficit information. 84

4.10.2 Trade Balance. 84

4.10.3 Production and investment Done in the recent Past 85

4.10.4 Initiatives Taken by Pharmaceutical Countries. 86

4.11 Supply Chain Distribution Channel 87

4.12 Suggestions and Opportunities For Italian Companies. 98

4.13 Industry Performance. 99

4.14 Industry Outlook. 100

4.14.1 Market Size and Growth. 100

4.14.2 Research and Development (R&D) 100

4.14.3 Market Dynamics. 100

4.14.4 Regulatory Landscape. 101

4.14.5 Market Access and Pricing. 101

4.14.6 COVID-19 Impact 101

4.14.7 Generics and Biosimilars. 101

4.14.8 Digital Health Integration. 101

4.14.9 Supply Chain Resilience. 102

4.14.10 Workforce and Employment 102

4.14.11 Downward Pressure on Pricing. 102

4.14.12 From Treatment to Prevention and Beyond. 103

4.15 Key External Drivers. 103

4.15.1 Increasing Geriatric Population. 103

4.15.2 Advantages Offered by Continuous Manufacturing Process. 104

4.16 Demand Determinants in Future. 104

4.16.1 Growing Interest of Pharmaceutical Companies to Promote Product Sales through Contract Sales Organizations. 104

4.16.2 Rising Number of Healthcare Start-ups. 105

4.17 Industry Trends in the US Market 106

4.17.1 Increasing Adoption of Continuous Manufacturing in Pharmaceuticals. 106

4.17.2 Growing Adoption of AI-based Tools for Drug Discovery. 106

4.17.3 Growing Adoption of Self-Injecting Parenteral Devices. 106

5. Pharmaceutical Market - Key Market Dynamics 110

5.1 Market Drivers. 110

5.1.1 Rising Workplace-Associated Disorders. 110

5.1.2 Rise in Pharmaceutical Production Capacity. 111

5.1.3 Increased Approvals of Generic Drugs. 112

5.1.4 Escalating R&D Investments in Pharmaceutical Industry. 112

5.2 Market Restraints. 113

5.2.1 High Cost of Drug Development and Marketing Approval 113

5.3 Market Opportunities. 113

5.3.1 Rising Incidences of Chronic Diseases and Infectious Diseases. 113

5.3.2 Emerging Markets for Outsourcing Production Activities. 114

5.4 Future Trends. 115

5.4.1 Increasing Adoption of AI-based Tools for Drug Discovery. 115

5.5 Impact Analysis. 116

6. Pharmaceutical Market - US Analysis 117

6.1 US Pharmaceutical Market Revenue Forecast and Analysis. 117

6.1.1 US: Pharmaceutical Market, by Product, 2019-2030 (US$ Billion) 118

6.1.1.1 US: Pharmaceuticals Market For Product, by Type, 2019-2030 (US$ Billion) 118

6.2 Production mapping. 119

6.2.1 Pharma companies in the US- 119

6.2.2 The impact of COVID-19 on R&D- 119

6.3 Pricing Analysis of Key Products. 119

6.4 Production and Sales Statistics of Pharmaceutical Market in US. 122

6.5 Value Chain Analysis and Vendor's Ecosystem.. 124

6.6 Go-to-Market Strategies for Companies. 125

6.6.1 Johnson & Johnson. 125

6.6.2 Pfizer Inc. 126

6.6.3 Merck Co & Inc. 126

6.7 Regulatory Scenario in the United States Associated With Pharmaceutical Industry. 127

6.7.1 Agencies, Organizations, Institutes, Centers, and Offices Associated with Pharmaceutical Product Regulation. 128

6.7.2 Regulations to enter and operate within the USA Market 128

6.8 HTS Codes for Drugs in United States. 129

6.8.1 Custom Duties. 131

6.8.2 Link Between HTS Codes and Custom Duties. 131

7. US Branded Small Molecules Market 132

7.1 US: Branded Small Molecules Market Revenue and Forecast to 2030. 132

7.1.1 Overview. 132

7.1.2 US: Branded Small Molecules Market Positioning Analysis. 134

7.1.3 US Branded Small Molecules Market - Revenue and Forecast to 2030 (USD Billion) 135

8. US Generic Small Molecules Market 136

8.1 US: Generic Small Molecules Market Revenue and Forecast to 2030. 136

8.1.1 Overview. 136

8.1.2 US: Generic Small Molecules Market Positioning Analysis: 138

8.1.3 US Generic Small Molecules Market - Revenue and Forecast to 2030 (USD Billion) 139

9. US Biological and Biosimilar Products Market 140

9.1 US: Biological and Biosimilar Products Market Revenue and Forecast to 2030. 140

9.1.1 Overview. 140

9.1.2 US: Biological and Biosimilar Products Market Positioning Analysis: 142

9.1.3 US Biological and Biosimilar Products Market - Revenue and Forecast to 2030 (USD Billion) 143

10. US Vaccines Market 144

10.1 US: Vaccines Market Revenue and Forecast to 2030. 144

10.1.1 Overview. 144

10.1.2 US: Vaccines Market Positioning Analysis: 146

10.1.3 US Vaccines Market - Revenue and Forecast to 2030 (USD Billion) 147

11. Pharmaceutical Market - Industry Landscape 148

11.1 Overview. 148

11.2 Growth Strategies in the Pharmaceutical Market 148

11.3 Inorganic Growth Strategies. 149

11.3.1 Overview. 149

11.4 Organic Growth Strategies. 150

11.4.1 Overview. 150

12. Company Profiles 152

12.1 Moderna Inc. 152

12.1.1 Key Facts. 152

12.1.2 Business Description. 152

12.1.3 Products and Services. 153

12.1.4 Financial Overview. 154

12.1.5 SWOT Analysis. 156

12.1.6 Key Developments. 158

12.2 AbbVie Inc. 159

12.2.1 Key Facts. 159

12.2.2 Business Description. 159

12.2.3 Products and Services. 160

12.2.4 Financial Overview. 161

12.2.5 SWOT Analysis. 164

12.2.6 Key Developments. 168

12.3 Gilead Sciences Inc. 169

12.3.1 Key Facts. 169

12.3.2 Business Description. 169

12.3.3 Products and Services. 170

12.3.4 Financial Overview. 171

12.3.5 SWOT Analysis. 173

12.3.6 Key Developments. 177

12.4 Regeneron Pharmaceuticals Inc. 178

12.4.1 Key Facts. 178

12.4.2 Business Description. 178

12.4.3 Products and Services. 179

12.4.4 Financial Overview. 180

12.4.5 SWOT Analysis. 181

12.4.6 Key Developments. 185

12.5 Merck & Co Inc. 186

12.5.1 Key Facts. 186

12.5.2 Business Description. 186

12.5.3 Products and Services. 187

12.5.4 Financial Overview. 188

12.5.5 SWOT Analysis. 191

12.5.6 Key Developments. 195

12.6 Abbott Laboratories. 196

12.6.1 Key Facts. 196

12.6.2 Business Description. 196

12.6.3 Products and Services. 197

12.6.4 Financial Overview. 199

12.6.5 SWOT Analysis. 202

12.6.6 Key Developments. 206

12.7 Bristol-Myers Squibb Co. 207

12.7.1 Key Facts. 207

12.7.2 Business Description. 207

12.7.3 Products and Services. 208

12.7.4 Financial Overview. 209

12.7.5 SWOT Analysis. 211

12.7.6 Key Developments. 215

12.8 Vertex Pharmaceuticals Inc. 216

12.8.1 Key Facts. 216

12.8.2 Business Description. 216

12.8.3 Products and Services. 217

12.8.4 Financial Overview. 218

12.8.5 SWOT Analysis. 220

12.8.6 Key Developments. 222

12.9 Pfizer Inc. 223

12.9.1 Key Facts. 223

12.9.2 Business Description. 223

12.9.3 Products and Services. 224

12.9.4 Financial Overview. 225

12.9.5 SWOT Analysis. 227

12.9.6 Key Developments. 231

12.10 Eli Lilly and Co. 233

12.10.1 Key Facts. 233

12.10.2 Business Description. 233

12.10.3 Products and Services. 234

12.10.4 Financial Overview. 235

12.10.5 SWOT Analysis. 237

12.10.6 Key Developments. 241

12.11 Bayer AG. 242

12.11.1 Key Facts. 242

12.11.2 Business Description. 242

12.11.3 Products and Services. 243

12.11.4 Financial Overview. 245

12.11.5 SWOT Analysis. 248

12.11.6 Key Developments. 251

12.12 Johnson & Johnson. 252

12.12.1 Key Facts. 252

12.12.2 Business Description. 252

12.12.3 Products and Services. 253

12.12.4 Financial Overview. 256

12.12.5 SWOT Analysis. 258

12.12.6 Key Developments. 262

12.13 Amgen Inc. 264

12.13.1 Key Facts. 264

12.13.2 Business Description. 264

12.13.3 Products and Services. 265

12.13.4 Financial Overview. 266

12.13.5 SWOT Analysis. 268

12.13.6 Key Developments. 272

12.14 Takeda Pharmaceutical Co Ltd. 273

12.14.1 Key Facts. 273

12.14.2 Business Description. 273

12.14.3 Products and Services. 274

12.14.4 Financial Overview. 275

12.14.5 SWOT Analysis. 278

12.14.6 Key Developments. 282

12.15 Zoetis Inc. 283

12.15.1 Key Facts. 283

12.15.2 Business Description. 283

12.15.3 Products and Services. 284

12.15.4 Financial Overview. 285

12.15.5 SWOT Analysis. 287

12.15.6 Key Developments. 290

LIST OF TABLES

Table 1. US Export Trade to Italy- Product: HSC 30 Pharmaceutical products. 43

Table 2. US Export Trade to Italy- Product: HSC 30 Pharmaceutical products. 44

Table 3. US Import Trade from Italy- Product: HSC 30 Pharmaceutical products. 47

Table 4. US Import Trade from Italy- Product: HSC 30 Pharmaceutical products. 48

Table 5. Italy Import Trade from US- Product: HSC 30 Pharmaceutical products. 54

Table 6. Italy Import Trade from US- Product: HSC 30 Pharmaceutical products. 55

Table 7. Italy Export Trade from US- Product: HSC 30 Pharmaceutical products. 58

Table 8. Italy Export Trade to US- Product: HSC 30 Pharmaceutical products. 59

Table 9. List of Magazines, Publications, Universities, and Online Portals. 61

Table 10. List of Events. 65

Table 11. List of Trade Shows. 67

Table 12. Events and Trade Shows. 68

Table 13. Counts of total nonfatal occupational injuries, illnesses, and respiratory illnesses (private industry, 2018-2022) (Thousand) 110

Table 14. US Pharmaceutical Market, by Product - Revenue and Forecast to 2030 (US$ Billion) 118

Table 15. US Pharmaceuticals Market For Product, by Type - Revenue and Forecast to 2030 (US$ Billion) 118

Table 16. Top Drugs by Price Increase, January and July 2022. 120

Table 17. Top Drugs by Percentage Price Increase, January and July 2022. 121

Table 18. Global Demand of Pharmaceutical (US$ Billion) 123

Table 19. Global Production of Pharmaceutical (US$ Billion) 123

Table 20. Production Size in US (US$ Billion) 123

Table 21. Novel Drug Approvals for 2023. 133

Table 22. Recent Generic Small Molecules Approvals by US FDA. 137

Table 23. Recent Biological and Biosimilar Products Approvals by US FDA. 141

Table 24. Recent Vaccines Approvals by US FDA. 145

Table 25. Recent Inorganic Growth Strategies in the Pharmaceutical Market 149

Table 26. Recent Organic Growth Strategies in the Pharmaceutical Market 151

LIST OF FIGURES

Figure 1. Pharmaceutical Market Overview.. 17

Figure 2. Small Molecules Segment Held Largest Share of Product Segment in Pharmaceutical Market 17

Figure 3. Pharmaceutical Market - Industry Landscape. 19

Figure 4. Experts' Opinion. 28

Figure 5. List of supplying markets for pharmaceutical product imported by United States. 37

Figure 6. List of supplying markets for pharmaceutical product imported by United States in US$ Thousand. 38

Figure 7. List of importing markets for a product exported by United States. 40

Figure 8. List of importing markets for a product exported by United States. 41

Figure 9. List of importing markets for a product exported by United States. 42

Figure 10. List of supplying markets for a product imported by Italy. 50

Figure 11. List of supplying markets for a product imported by Italy. 50

Figure 12. List of importing markets for a product exported by Italy. 51

Figure 13. List of importing markets for a product exported by Italy. 52

Figure 14. List of importing markets for a product exported by Italy. 53

Figure 15. Key Trends Impact 108

Figure 16. Key Trends Impact 109

Figure 17. Pharmaceutical Market Impact Analysis of Driver and Restraints. 116

Figure 18. US Pharmaceutical Market - Revenue Forecast and Analysis - 2020-2030. 117

Figure 19. US Branded Small Molecules Market Revenue and Forecast to 2030 (USD Billion) 135

Figure 20. US Generic Small Molecules Market Revenue and Forecast to 2030 (USD Billion) 139

Figure 21. US Biological and Biosimilar Products Market Revenue and Forecast to 2030 (USD Billion) 143

Figure 22. US Biological and Biosimilar Products Market Revenue and Forecast to 2030 (USD Billion) 147

Figure 23. Growth Strategies in the Pharmaceutical Market 148